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Abstract:  
Background: Studying the neural consequences of tobacco smoking during adolescence, 
including those associated with early light use, may inform the mechanisms that underlie the 
transition from initial use to nicotine dependence in adulthood. However, only a few studies in 
adolescents have appeared and those available include small samples. In addition, the neural 
mechanism, if one exists, that links nicotinic receptor genes to smoking behavior in adolescents is 
still unknown.  
Methods: Structural and diffusion tensor magnetic resonance imaging data were acquired from a 
large sample of 14-year-old adolescents who completed an extensive battery of 
neuropsychological, clinical, personality and drug use assessments. Additional assessments were 
conducted at age 16.   
Results: Exposure to smoking in adolescents, even at low doses, is linked to volume changes in 
the ventromedial prefrontal cortex and to altered neuronal connectivity in the corpus callosum. The 
longitudinal analyses strongly suggest that these effects are not pre-existing conditions in those 
who progress to smoking. There was a genetic contribution wherein the volume reduction effects 
were magnified in smokers who were carriers of the high-risk genotype of the alpha 5 nicotinic 
receptor subunit gene, rs16969968.  
Conclusions: These findings give insight into a mechanism involving genes, brain structure and 
connectivity underlying why some adolescents find nicotine especially reinforcing. 
 
 
 
 
 
 
 
 
4 
 
 
 
Introduction 
Smoking is the leading cause of preventable death in the United States and other developed 
countries. According to the U.S. Centers for Disease Control and Prevention (www.cdc.gov), 
smoking causes nearly six million deaths per year globally; current trends predict this will reach 
eight million by 2030. Using the U.S. as an example, more than five million Americans under 18 
today are expected to die from a smoking-related illness, which is higher than the number of deaths 
caused by HIV, drug misuse, suicide, murder and motor vehicle injuries, combined. Smoking starts 
primarily during adolescence, with about 90% of US smokers reporting that they tried smoking 
before the age of 18. Every day in the US alone, 3,800 adolescents smoke their first cigarette and 
2,100 become daily smokers. These statistics are particularly troubling given that early use of 
cigarettes during adolescence has been associated with heightened risk for later dependence (1,2). 
Remarkably, even relatively low rates of cigarette consumption during adolescence (e.g., two to 
four cigarettes per week) increase the risk of becoming nicotine dependent by early adulthood 
(1,3). 
Adolescence is a period of considerable brain development (4,5) and it has been 
hypothesized that nicotine use during this critical period produces neurobiological changes that 
promote tobacco dependence later in life (6). Thus, studying the neural consequences of smoking 
during adolescence, including those associated with early use, may inform the mechanisms that 
underlie the transition from initial use to nicotine dependence in adulthood. In contrast to the 
extensive literature on adult smokers, few studies in adolescents have appeared and those available 
include small samples.  
Nicotine dependence is highly heritable (7) and genome-wide association studies have 
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revealed a reliable association between dependence and single nucleotide polymorphisms (SNPs) 
at the 15q nicotinic acetylcholine receptor (nAChR) α5-α3-β4 gene cluster (8–10). The most 
replicated SNPs associated with smoking and lung cancer are the α3 subunit gene (CHRNA3) 
rs1051730 (11,12) and the α5 subunit gene (CHRNA5) rs16969968 (8), which both convert 
aspartic acid (G allele) to asparagine (A allele), with A being the risk-allele. However, the neural 
mechanisms, if any exist, that link these SNPs to smoking are poorly understood. One possible 
mechanism linking the polymorphism to nicotine dependence is reduced dopamine-mediated 
reward processing due to A allele nAChR expression (9). For example, Sherva et al. concluded 
that the A allele was significantly related to enhanced pleasurable responses to a person’s first 
cigarette (10). Hong et al. showed that rs16969968 is associated with a dorsal anterior cingulate–
ventral striatal/extended amygdala circuit, in which the risk-allele was associated with decreased 
intrinsic resting functional connectivity strength in smokers and, to a lesser extent, nonsmokers. 
Further, the connectivity strength of the circuit distinguished smokers from nonsmokers and 
predicted addiction severity in smokers (13).  
In the present study, we sought to determine how these genetic predispositions might 
impact the morphometry of the developing adolescent brain and its relationship to smoking. We 
were specifically interested in the genetic influence of the CHRNA3 SNP rs1051730 and the 
CHRNA5 SNP rs16969968 on initial cigarette use in order to illuminate possible pathways that 
lead to heavier use and dependence. Using multimodal neuroimaging in a large cohort of 14 years 
old adolescents from the IMAGEN study (http://www.imagen-europe.com), we first determined 
grey matter volume (GMV) differences in both early smokers and nonsmokers followed by the 
influence of the above two SNPs. Then, we measured white matter connectivity to determine the 
anatomical structural connectivity that may have supported these genetic polymorphism findings.  
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We hypothesize, based on previous neuroimaging studies, to find a smoking association 
with GMV mainly in the prefrontal cortex (14–16), and with white matter connectivity mainly in 
the corpus callosum (17–19). We also hypothesize, based on previous GWAS findings (8), to 
observe a small but significant association between CHRNA5 and smoking behavior. 
 
Materials and Methods 
Overview of IMAGEN protocols 
Full details of the procedures employed by the IMAGEN study, including details on ethics, 
recruitment, standardized instructions for administration of the psychometric and cognitive 
behavioral measures are available in the standard operating procedures for the IMAGEN project 
(http://www.imagen-europe.com/en/Publications_and_SOP.php).  
 
Participants  
Data were acquired from 14-year-old adolescents. After complete description of the study 
to the participants and their parents/guardians, written informed consent was obtained. Individuals 
who provided assent completed an extensive battery of neuropsychological, clinical, personality 
and drug use assessments online and at the testing centers. Additional assessments were conducted 
at age 16. Participants were excluded if they had contraindications for MRI (metal or electronic 
implants and claustrophobia) or problematic medical history (e.g., diabetes, tumors, heart defects), 
neurological conditions (e.g., epilepsy, head trauma, neurodevelopmental disorders such as 
ADHD, OCD, depression and anxiety) or low IQ (<70).  The Wechsler intelligence scale for 
children was used to measure IQ and was administered by experimenters at the study centers. The 
vocabulary and similarities subscales were employed to determine verbal IQ. The block design, 
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matrix reasoning and digit span subscales were employed to determine non-verbal/performance 
IQ. A puberty score was calculated using the Pubertal Development Scale (PDS) scale (20), which 
consisted of asking adolescents about physical development traits, such as growth in height, body 
hair, skin changes, and other gender-specific traits (i.e. voice deepening, menstruation). The PDS 
category scores (answers) are as follows: 1 (No), 2 (Yes (Barely)), 3 (Yes (Definitely)), 4 
(Development Completed).  Data were normed according to the subject's age.  
 
Smoking score 
A cigarette-smoking score was calculated for the 14 year old adolescents from the European 
School Survey Project on Alcohol and Drugs (ESPAD) (21)  questionnaire, which asked: “On how 
many occasions (if any) during your lifetime have you smoked cigarettes?”. The ESPAD category 
scores are as follows: Score (Lifetime occurrences): 0 (0), 1 (1-2), 2 (3-5), 3 (6-9), 4 (10-19), 5 
(20-39), 6 (>40).  Follow-up smoking scores at age 16 were also collected. To account for second-
hand smoke exposure, parent smoking scores were calculated using the same ESPAD 
questionnaire. These scores were not significantly different between smokers and non-smokers in 
the sample (1.6±0.5 vs 1.3±0.8, respectively), with p=0.23. Similar data using the same scoring 
system were obtained for alcohol use where an alcohol score was calculated from a similar ESPAD 
questionnaire which asked: “On how many occasions (if any) during your lifetime have you had 
any alcoholic beverage to drink?”. 
Different numbers of smokers and non-smokers were available for the neuroimaging and 
genetic analyses, which is graphically presented in Figure 1 and subject demographics detailed in 
supplementary Table 1.  
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Neuroimaging  
 MRI acquisition  
MRI scanning was performed at the eight IMAGEN assessment sites (London, 
Nottingham, Dublin, Mannheim, Dresden, Berlin, Hamburg, and Paris) with 3T whole body MRI 
systems made by several manufacturers (Siemens: 4 sites, Philips: 2 sites, General Electric: 1 site, 
and Bruker: 1 site). To ensure comparability of MRI data acquired on these different scanners, 
image-acquisition techniques were implemented using a set of parameters compatible with all 
scanners that were held constant across sites, for example, those directly affecting image contrast 
or fMRI preprocessing. The full details of the MRI acquisition protocols and quality checks have 
been described previously, including the extensive period of standardization across MRI scanners 
(22). 
 
Structural MRI 
High-resolution anatomical MRIs were acquired with a three-dimensional T1 weighted 
magnetization prepared gradient echo sequence (MPRAGE) based on the ADNI protocol 
(http://www.loni.ucla.edu/ADNI/Cores/index.shtml).  
 
Diffusion MRI 
Diffusion weighted images were acquired with a single-shot EPI sequence with a b value 
of 1300 s/mm2, a TE of 104 ms and a voxel size of 2.4x2.4x2.4mm, with 60 slices providing whole-
brain coverage.  
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MRI data preprocessing  
Preprocessing of the structural T1-weighted data was performed centrally with the 
Statistical Parametric Mapping version 8 (Wellcome Department of Neuroimaging, London, 
United Kingdom, http://www.fil.ion.ucl.ac.uk/spm/software/spm8/), using standard automated 
pipelines (22). Structural T1-weighted MRI processing included image segmentation into grey 
matter (GM), white matter and cerebrospinal fluid tissue classes, preceded by an iterative 
registration to the Montreal Neurological Institute (MNI) template space, using SPM’s optimized 
normalization routine (23). For voxel-based morphometry (VBM), gray matter images were 
smoothed with a Full Width at Half Maximum (FWHM) Gaussian kernel of 8 mm, warped to 
standard MNI space and modulated by multiplying the linear and non-linear component of the 
Jacobian determinants generated during spatial normalization. Thus, the dependent measure in 
subsequent statistical analyses was absolute grey matter volume (GMV), facilitating comparisons 
of volumetric, rather than tissue concentration differences (24).  
The Diffusion Tensor Imaging (DTI) preprocessing was performed with FSL 4.1 
(www.fmrib.ox.ac.uk/fsl). The pipeline consisted of the following steps: First, Eddy-current and 
motion correction were applied using an affine registration and the B0 volume of the DTI data as 
reference. After registration, a brain extraction was applied to remove non-brain tissues and a first 
estimation of the diffusion tensor was achieved for each voxel. After B0 unwarping using the 
magnitude and phase images from the fieldmap acquisition, a second estimation of the diffusion 
tensor was achieved for each voxel. Finally, Fractional Anisotropy (FA) maps were generated for 
each subject. 
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Genetics 
Genotyping and Quality control 
DNA purification and genotyping was performed by the Centre National de Génotypage in 
Paris. DNA was extracted from whole blood samples preserved in ethylene-eiamine-tetra-acetic 
acid vacutainer tubes (BD, Becton, Dickinson and Company, Oxford, United Kingdom) using 
Gentra Puregene Blood Kit (QIAGEN, Valencia, California) according to the manufacturer’s 
instructions. Genotype information was collected at 582,892 markers using the Illumina 
HumanHap610 and HumanHap660 Genotyping BeadChips (San Diego, California). The SNPs 
with call rates of <95%, minor allele frequency < 1%, deviation from the Hardy-Weinberg 
equilibrium (p ≤ 1E-06), and non-autosomal SNPs were excluded.  
 
Imputation of markers data 
Markers data imputation and quality control for ambiguous SNPs, low MAF, missingness 
and HWE were done with MACH (25) following the ENIGMA2 guidelines (26). The 1000 
Genomes project reference set of markers (http://www.1000genomes.org/data) was used for the 
imputation after decreasing the markers from ~41 million to ~13 million relevant genetic variants 
observed more than once in the European populations (26). Both rs16969968 and rs1051730 data 
were imputed and had good imputation quality (R2 imputation quality metric ≥ 0.87) 
(supplementary Table 2).  
 
Missing demographic data 
Participants with missing data on sex and/or site were excluded. Missing values on 
continuous variables were replaced with the mean derived according to the participant’s site and 
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sex. Missing values on nominal data were replaced with the mode of that variable for the 
participant’s site and sex. The maximal missing rate for each variable was lower than 10%.  
Statistical Analyses  
Single SNP association analysis  
Genotype effects of rs16969968 and rs1051730 on smoking levels were examined using 
single SNP linear regression in the 1417 subjects included in the genetic analysis (described in 
supplementary Fig 1-c and supplementary Table 1-Genetic analysis). The frequencies of the high-
risk, the intermediate risk and the normal (no risk) genotypes for the two SNPs are described in 
supplementary Table 2. Four multidimensional scaling components were calculated using a metric 
model to account for population stratification and were included, in addition to age and gender, as 
covariates in an additive regression model (genotypes coded as 0, 1, and 2 for the number of risk 
alleles). These analyses were performed using PLINK v1.9 
(http://pngu.mgh.harvard.edu/~purcell/plink/). No other SNPs were investigated in this study. 
 
Brain voxel-wise analyses 
Whole brain voxel-wise multiple regression analyses were performed on GMV and FA 
maps to identify regions significantly correlated with the smoking score and test whether effects 
were observable across the full range of smoking exposure levels (i.e. scores 0-6). These analyses 
were carried out using the general linear model, performed with the VBM toolbox of SPM8. Age, 
sex, PDS, handedness, scanner site (dummy coded), Performance IQ, Verbal IQ, socio-economic 
status and total GMV (only for GMV analyses) were included as nuisance covariates in the design 
matrix in all analyses. Performance IQ was significantly lower and alcohol use significantly higher 
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in smokers (p’s<0.05) and were included in the subsequent ROI-level analyses. The other variables 
were not different between the two groups (p’s>0.1).  
The resulting set of voxel values constituted a Statistical Parametric Map of the t statistic 
(SPM{t}). We used 3dClustSim, a cluster correction Monte Carlo procedure available in AFNI 
(http://afni.nimh.nih.gov/), to determine a minimum cluster size that achieves a corrected 
significance of p <0.05 with a voxel-wise threshold of p < 0.001 and a Full Width at Half Maximum 
(FWHM) spatial blur that is empirically derived from the spatial autocorrelation in the datasets 
(residuals from the voxelwise statistical analyses). Clusters with a spatial extent threshold > 411 
voxels were considered significantly related to smoking levels.  
 
ROI-level analysis  
The mean GMV was extracted with the Marsbar toolbox (27) from the ROI that the VBM 
regression analysis revealed to be significantly associated with smoking. GMV values were then 
included as a dependent variable in a 2 (smoking status) by 3 (genotype) ANCOVA model to test 
the interaction between smoking and genotype on GMV. In this model, subjects were grouped into 
smokers (score = 1-6) and non-smokers (score = 0) then into the three genotypes (AA, GA and 
GG). Further, the mean FA was extracted from the ROI obtained from the DTI regression analysis 
that was significantly associated with smoking and then included as a dependent variable in a 
similar ANCOVA model to test the interaction between smoking amount and genotype on FA.  
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Results 
Smoking status and CHRNA genotype effects on structural variations in the cortex 
First, we studied the neuroanatomical correlates of cigarette use in grey matter density in 
211 adolescent smokers from the cohort who had VBM data passing quality control and very low 
to moderate smoking exposure (smoking scores 1-6), compared with 627 non-smokers (Figure 1-
A). A whole brain VBM regression analysis showed a significant negative linear relation between 
GMV and smoking scores (r = -0.2, p = 5E-06, df=822) in the ventromedial prefrontal cortex 
(vmPFC) (cluster size: 499 voxels; cluster peak coordinates:  x = 6, y = 30, z = -12) after p < 0.05 
cluster-wise correction (Figure 2-A).  
We next replicated the association of the rs16969968 genotype previously reported in 
smokers (9) in 940 non-smokers and 477 smokers across all smoking ranges (Figure 1-C) 
(p=0.003), which explained ~ 3.5% of smoking behavior variance in the sample (Supplementary 
Table 2). Analyses of the rs1051730 SNP revealed a similar result to that seen for rs16969968, 
which is not surprising given their strong linkage disequilibrium (D’=1; R2 = 0.99; supplementary 
Table 2). Assuming that rs16969968 is the functional locus (9), results from rs1051730 are not 
reported further and subsequent analyses are restricted to rs16969968. 
Next, we studied smoking exposure * genotype interaction effects on the lower vmPFC 
volume derived from the whole brain regression analysis that provided the vmPFC ROI used for 
subsequent analyses. A 2 (smoking status) by 3 (genotype) ANCOVA indicated that smoking 
status (all smoking-exposure levels; p < 0.0005) and the smoking*genotype interaction (p = 0.02) 
had significant effects on the vmPFC volume (Figure 2-C); there was no significant main effect 
for genotype in either the whole sample or in non-smokers (p > 0.09). Notably, the ANCOVA 
showed that the vmPFC volume was significantly lower in smokers in each of the three genotypes, 
14 
 
compared with non-smokers (p = 0.000012), with the largest effect in homozygote carriers of the 
high-risk alleles (AA genotype; n= 18 smokers and n = 58 non-smokers). Moreover, smoking 
levels did not differ significantly among the three genotype groups (p=0.1). 
 
Alcohol use and Performance IQ effects in smokers 
In our sample, alcohol use and performance IQ were significantly associated with 
smoking (supplementary Table 1), thus rendering it difficult to attribute the vmPFC anatomical 
and functional effects to smoking per se. To address this, we identified 341 non-smokers and 
assessed the correlations between alcohol use (alcohol scores ranging from 0-6 reflecting the 
same ranges of lifetime use as defined for smoking) and performance IQ with the volumetric 
measures for the vmPFC. The same covariates were included as above. The results yielded no 
significant associations with alcohol use (R2 < 0.0005, p > 0.1, df=326) or performance IQ (R2 
< 0.01, p > 0.05, df=325) (Figure 3). These results strongly suggest that alcohol use and 
performance IQ, on their own (i.e., in non-smokers), do not significantly impact the volumetric 
effects in the vmPFC and thus are unlikely to be the source of the observed genetic effects in 
smokers. 
 
Smoking status effects on white matter  
Finally, we examined the connectivity of the white matter as a function of smoking. Using 
the same covariates as in the previous analyses (except for total GMV), we performed a whole-
brain regression on a sample of 147 smokers and 529 non-smokers for a total of 676 subjects 
(Figure 1-B). The analysis yielded a significant negative correlation (r=-0.24, p = 5E-06, df=661) 
between FA and smoking scores, in the anterior corpus callosum (359 voxels, x=-15, y=30, z=10) 
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after p corrected<0.05 (Figure 4-A), reflecting altered inter-hemispheric axonal structural 
properties with smoking and revealing a linear relationship similar to what was observed between 
the vmPFC volume and smoking. Finally, a 2 X 3 ANCOVA revealed no significant interaction 
between smoking and genotype on FA extracted from the corpus callosum ROI (p>0.1). While this 
could be explained by the lack of statistical power due to the loss of a significant number of heavier 
smokers who did not have DTI data, it is also possible that the nicotinic receptor genetic influence 
was manifest on GMV but not white matter connectivity.    
 
Discussion 
In this study, we have shown that exposure to tobacco smoking in adolescents, even at low 
doses, is linked to a reduction in vmPFC gray matter volume and altered neuronal connectivity in 
the corpus callosum. Most notably, the regression analyses indicate linear reductions in vmPFC 
volumes and neuronal connectivity observable in the very light smoking group of young 
adolescents. Finally, there was a small yet interesting genetic contribution wherein the vmPFC 
volume reduction effects were magnified in smokers who were carriers of the high-risk 
polymorphisms of the alpha 5/alpha 3 nicotinic receptor subunits. The absence of both main effects 
of genotype and any genotype effects in non-smokers indicates a gene * exposure interaction such 
that the effects of the polymorphisms are only evident if the adolescent is a smoker.   
Our structural findings are in line with numerous VBM studies reporting negative dose-
response correlations between the PFC volume/density in general (14–16) or the vmPFC volume 
in particular (28) and lifetime cigarette usage in adult heavy smokers. Notably, the present results 
show this relationship in a group of relatively inexperienced adolescent smokers and suggests the 
linear decrease is present even at the lightest levels of smoking. These results support a growing 
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literature suggesting that smoking particularly affects the PFC, either from nicotine or one of the 
more than four thousand chemicals present in tobacco, about 400 of which, including nicotine and 
CO, are known toxins (29). 
Despite the converging evidence of apparent brain atrophy in moderate and heavy adult 
smokers in the PFC (14–16), the dose-response relationship observed in our data is intriguing as it 
suggests that just one or two cigarettes can potentially alter adolescent cortex development, an 
observation that has not been previously reported. An alternative interpretation is that the lower 
vmPFC GMV preceded and predisposed toward smoking initiation. To address this possibility, we 
assessed the relationship between vmPFC volume at age 14 and future smoking at age 16 in 627 
adolescents who were smoking naïve at age 14, using the same covariates included in the previous 
regression analyses. Within this sample of adolescents, 386 remained never-smokers at age 16 with 
the remaining 241 showing a similar use distribution in smoking levels at age 16 as was observed 
in the previous analysis of smokers at age 14 (see Figure 1). The vmPFC volume derived from the 
age 14 regression analysis did not predict future smoking at age 16 (β = 0.02, p = 0.9, 
df=611) (Figure 2-B), which does not support the hypothesis that the observed volume reduction 
predisposed towards adolescent use. Rather, this finding is consistent with the interpretation that 
even extremely low smoking exposure by age 14 may influence brain maturation in early 
adolescence.  
The association of the rs16969968 genotype with smoking behavior is consistent with Hong 
et al (30) who showed that rs16969968 genotype significantly explains 3.3% and 4.6% of the 
variance of nicotine addiction severity and cigarettes per day, respectively. The gene*exposure 
vmPFC effect is consistent with a recent meta-analysis (31) of pharmacological neuroimaging 
studies which revealed that cigarette smoking and CHRNA agonist administration in adult smokers 
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are both associated with lower neural activity in, among other regions, the vmPFC. In line with 
these findings, another meta-analysis, interrogating the neurobiological targets of pharmacological 
and cognitive-based treatments for addiction to nicotine, identified similar portions of the vmPFC 
to have lower activity in smokers (32). Moreover, the rs16969968 * smoking interaction provides 
evidence that nicotine, rather than the other chemicals in cigarettes, might be the basis of the 
association between smoking and GMV reductions modulated by the nicotinic acetylcholine 
receptor system.  
The DTI findings are in line with previous data showing that smokers have lower white 
matter FA in the anterior corpus callosum (17–19), which has been interpreted to indicate possible 
axonal damage and disrupted myelin integrity in the region (19). Conversely, other studies have 
reported higher (33) or unchanged FA (34) in the corpus callosum of smokers. This discordance 
could be explained by the fact that the used sample differed by age, size and/or smoking exposure. 
Similar to the GMV findings, FA differences were observed even in very light smokers. To address 
the possibility that the reduced FA values, like the reduced vmPFC GMV, preceded smoking, we 
similarly assessed the relationship between anterior corpus callosum FA at age 14 and future 
smoking at age 16 in 531 adolescents who were smoking naïve at age 14 (348 never-smokers and 
183 smokers), using the same covariates as in the previous FA analyses. The anterior corpus 
callosum FA, derived from the regression analysis, did not predict future smoking (r=0.02, p=0.89, 
df=516) (Figure 4-B), which supports the conclusion that the FA reduction did not precede 
adolescent use but rather that very low smoking exposure appears to alter adolescent brain 
development.  
Since the anterior corpus callosum connects regions of the prefrontal cortex with 
morphologically similar regions in the opposite hemisphere (35), we next asked if the anterior 
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corpus callosum FA reduction was related to the vmPFC volume reduction of the age 14 smokers. 
There was a significant positive correlation between the two in smokers and non-smokers (r=0.25, 
p<0.0001, df=615; Figure 4-C) within 630 adolescents (498 non-smokers and 132 smokers) from 
the sample used for the whole brain FA regression analysis who also had GMV data. Finally, while 
the absence of interaction between smoking and genotype on FA could be explained by the lack of 
statistical power due to the loss of a significant number of heavier smokers who did not have DTI 
data, it is also possible that the nicotinic receptor genetic influence was manifest on grey matter 
volume but not white matter connectivity.    
The key limitation of the present study is the sample size for the genetic analyses. With 
1417 participants on whom genetic data was available (940 non-smokers, 417 smokers), we are at 
the lower limit of the genetic-association approaches for estimating contributions of common SNPs 
to phenotypic variations, especially because individual SNPs only explain small amounts of this 
variance. The limited sample size also affected the significance values in the brain-genotype 
interaction analysis where we ended up with a small group (N=18) of smokers having the double 
risk allele. The genetic findings must be therefore interpreted in light of the sample size limitations. 
Nevertheless, this sample size limitation must be viewed in the context of the phenotype under 
study. In fact, the IMAGEN dataset is currently the largest longitudinal brain imaging and genetics 
study in adolescents worldwide, allowing us to detect unique relationships, even if small, between 
the brain, genetics and smoking behavior. 
Combined, this study’s results indicate a structural and functional basis for dose-response 
changes in the brain of young adolescent smokers, which may underlie, at least in part, the known 
CHRNA genetic association with smoking. The longitudinal analyses suggest that these effects are 
not pre-existing conditions in those who progress to smoking, but rather may be, in the case of 
19 
 
GMV for example, an initial phase of volume reductions of the PFC in general and the vmPFC in 
particular that have been observed in adult heavy smokers (14–16,28). Although adolescent 
experimentation with smoking is common, these results give insight into a mechanism involving 
genes, brain structure and brain connectivity underlying why some teens find nicotine especially 
reinforcing and transition to repeated use leading to increased risk of lifetime dependence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
 
Acknowledgments:  
This work received support from the following sources: P50DA036114 from the National 
Institute on Drug Abuse and Food and Drug Administration; P20GM103644 from the National 
Institute on General Medical Sciences; the European Union-funded FP6 Integrated Project 
IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) 
(LSHM-CT- 2007-037286), the FP7 projects IMAGEMEND (602450; IMAging GEnetics for 
MENtal Disorders) and MATRICS (603016), the Innovative Medicine Initiative Project EU-AIMS 
(115300-2), a Medical Research Council Programme Grant ‘‘Developmental pathways into 
adolescent substance abuse’’ (93558), the Swedish funding agency FORMAS, the Medical 
Research Council and the Wellcome Trust(Behavioural and Clinical Neuroscience Institute, 
University of Cambridge), the National Institute for Health Research (NIHR) Biomedical Research 
Centre at SouthLondon and Maudsley NHS Foundation Trust and King’s College London, the 
Bundesministerium fur Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; eMED 
SysAlc 01ZX1311A; Forschungsnetz AERIAL), the Deutsche Forschungsgemeinschaft (DFG): 
Reinhart-Koselleck Award SP 383/5-1 and grants SM 80/7-1, SFB 940/1, FOR 1617), the French 
MILDT (Mission Interministe rielle de Lutte contre la Drogue et la Toxicomanie), the CENIR 
(Centre de NeuroImagerie de Recherche, Pr. S. Lehe ricy) within the ICM institute, the National 
Institute of Mental Health (MH082116), and a National Institutes of Health Center of Biomedical 
Research Excellence award P20GM103644 from the National Institute of General Medical 
Sciences and the Tobacco Centers of Regulatory Science award P50DA036114. HG was 
supported, in part, by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance 
that funds Big Data to Knowledge Centers of Excellence. 
21 
 
G.S. is the primary investigator of the IMAGEN Consortium. T.B., G.B, A.L.W.B., U. B., 
C.B., A.C., P.J.C., S.D., H.F., V.F., J.G., P.G., A.H., B.I., J.-L.M., M-L.P-M., F.N., D.P.O.,L. P., 
T.P., M.N.S., H.W., R.W., G.S. and H.G acquired and pre-processed the data. B.C. and H.G. 
carried out the analyses and wrote the manuscript. K.J.K., S.M., P.S., N.D., K.E.H. & C.O. 
assisted in analytic methods. E.A.S., S.T.H., A.P., & R.R.A. provided expert advice and edited 
the manuscript. 
Members of the IMAGEN Consortium not listed as individual authors include: Karl Mann, 
Maren Struve, Marcella Rietschel, Rainer Spanagel, Mira Fauth-Bühler, Sabina Millenet, and 
Yvonne Grimmer at the Central Institute of Mental Health, University of Heidelberg; Nikolay 
Ivanov, Nicole Strache, Michael Rapp, Andreas Ströhle, and Jan Reuter at Charité, 
Universitätsmedizin Berlin; Alexis Barbot, Benjamin Thyreau, Yannick Schwartz, and Christophe 
Lalanne at the Comissariat à l’Energie Atomique; Jean-Luc Martinot, Zuleima Bricaud, Fanny 
Gollier Briand, Hervé Lemaitre, Jessica Massicotte, Helene Vulser, Jani Pentillä, and André 
Galinowski at the Institut national de la santé et de la recherche médicale; Tianye Jia, Helen Werts, 
Lauren Topper, Laurence Reed, Chris Andrew, Catherine Mallik, Barbara Ruggeri, Charlotte 
Nymberg, Lindsay Smith, Eva Loth, Stephanie Havatzias, Kerstin Stueber, and Argyris Stringaris 
at the Institute of Psychiatry, King’s College London; Patrick Constant at PERTIMM 
(AsnièresSur-Seine); Ruediger Brühl, Albrecht Ihlenfeld, and Bernadeta Walaszek at the 
PhysikalischTechnische Bundesanstalt; Thomas Hübner, Kathrin Müller, Stephan Ripke, Sarah 
Rodehacke, Eva Mennigen, Dirk Schmidt, NoraVetter, and Veronika Ziesch at the Technische 
Universität Dresden; Jennifer Jones at the University College Dublin; Jean-Baptiste Poline at the 
University of California, Berkeley; Tahmine Fadai, Juliana Yacubian, and Sophia Schneider at the 
22 
 
University of Hamburg; Claire Lawrence, Craig Newman, Kay Head, and Nadja Heym at the 
University of Nottingham; and Zdenka Pausova, and Amir Tahmasebi at the University of Toronto. 
 
Conflict of interest 
The authors declare that there are not any competing financial interests in relation to the work 
described.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
References: 
1.  Lydon DM, Wilson SJ, Child A, Geier CF. Adolescent Brain Maturation and Smoking: 
What We Know and Where We’re Headed. Neurosci Biobehav Rev. 2014 Sep;45:323–42.  
2.  Kendler KS, Myers J, Damaj MI, Chen X. Early smoking onset and risk for subsequent 
nicotine dependence: a monozygotic co-twin control study. Am J Psychiatry. 2013 
Apr;170(4):408–13.  
3.  Riggs NR, Chou C-P, Li C, Pentz MA. Adolescent to emerging adulthood smoking 
trajectories: when do smoking trajectories diverge, and do they predict early adulthood 
nicotine dependence? Nicotine Tob Res Off J Soc Res Nicotine Tob. 2007 Nov;9(11):1147–
54.  
4.  Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during 
adolescence? Nat Rev Neurosci. 2008 Dec;9(12):947–57.  
5.  Miguel-Hidalgo JJ. Brain structural and functional changes in adolescents with psychiatric 
disorders. Int J Adolesc Med Health. 2013;25(3):245–56.  
6.  DeBry SC, Tiffany ST. Tobacco-induced neurotoxicity of adolescent cognitive 
development (TINACD): a proposed model for the development of impulsivity in nicotine 
dependence. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2008 Jan;10(1):11–25.  
7.  Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine 
dependence and pharmacotherapy. Biochem Pharmacol. 2008 Jan 1;75(1):178–95.  
8.  Bierut LJ. Convergence of genetic findings for nicotine dependence and smoking related 
diseases with chromosome 15q24-25. Trends Pharmacol Sci. 2010 Jan;31(1):46–51.  
9.  Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. Variants in 
nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008 
Sep;165(9):1163–71.  
10.  Sherva R, Wilhelmsen K, Pomerleau CS, Chasse SA, Rice JP, Snedecor SM, et al. 
Association of a single nucleotide polymorphism in neuronal acetylcholine receptor subunit 
alpha 5 (CHRNA5) with smoking status and with “pleasurable buzz” during early 
experimentation with smoking. Addict Abingdon Engl. 2008 Sep;103(9):1544–52.  
11.  Leung T, Bergen A, Munafò MR, De Ruyck K, Selby P, De Luca V. Effect of the 
rs1051730–rs16969968 variant and smoking cessation treatment: a meta-analysis. 
Pharmacogenomics. 2015 May 1;16(7):713–20.  
12.  Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MFG, Aveyard P. CHRNA3 
rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res Off J Soc Res 
Nicotine Tob. 2011 Oct;13(10):982–8.  
24 
 
13.  Hong LE, Hodgkinson CA, Yang Y, Sampath H, Ross TJ, Buchholz B, et al. A genetically 
modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad 
Sci. 2010 Jul 27;107(30):13509–14.  
14.  Brody AL, Mandelkern MA, Jarvik ME, Lee GS, Smith EC, Huang JC, et al. Differences 
between smokers and nonsmokers in regional gray matter volumes and densities. Biol 
Psychiatry. 2004 Jan 1;55(1):77–84.  
15.  Gallinat J, Meisenzahl E, Jacobsen LK, Kalus P, Bierbrauer J, Kienast T, et al. Smoking 
and structural brain deficits: a volumetric MR investigation. Eur J Neurosci. 2006 Sep 
1;24(6):1744–50.  
16.  Zhang X, Salmeron BJ, Ross TJ, Geng X, Yang Y, Stein EA. Factors underlying prefrontal 
and insula structural alterations in smokers. NeuroImage. 2011 Jan 1;54(1):42–8.  
17.  Lin F, Wu G, Zhu L, Lei H. Heavy smokers show abnormal microstructural integrity in the 
anterior corpus callosum: a diffusion tensor imaging study with tract-based spatial statistics. 
Drug Alcohol Depend. 2013 Apr 1;129(1–2):82–7.  
18.  Savjani RR, Velasquez KM, Thompson-Lake DGY, Baldwin PR, Eagleman DM, De La 
Garza R, et al. Characterizing white matter changes in cigarette smokers via diffusion tensor 
imaging. Drug Alcohol Depend. 2014 Dec 1;145:134–42.  
19.  Viswanath H, Velasquez KM, Thompson-Lake DGY, Savjani R, Carter AQ, Eagleman D, 
et al. Alterations in interhemispheric functional and anatomical connectivity are associated 
with tobacco smoking in humans. Front Hum Neurosci [Internet]. 2015 Mar 9 [cited 2016 
Feb 3];9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353249/ 
20.  Petersen AC, Crockett L, Richards M, Boxer A. A self-report measure of pubertal status: 
Reliability, validity, and initial norms. J Youth Adolesc. 1988 Apr;17(2):117–33.  
21.  Hibell B. The 1995 ESPAD report: alcohol and other drug use among students in 26 
European countries. European School Survey Project on Alcohol and other Drugs, editor. 
1997;  
22.  Schumann G, Loth E, Banaschewski T, Barbot A, Barker G, Büchel C, et al. The IMAGEN 
study: reinforcement-related behaviour in normal brain function and psychopathology. Mol 
Psychiatry. 2010 Dec;15(12):1128–39.  
23.  Ashburner J, Friston KJ. Unified segmentation. NeuroImage. 2005 Jul 1;26(3):839–51.  
24.  Ashburner J, Friston KJ. Voxel-Based Morphometry—The Methods. NeuroImage. 2000 
Jun;11(6):805–21.  
25.  Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data 
to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010 Dec;34(8):816–
34.  
25 
 
26.  ENIGMA2 Genetics Support Team. ENIGMA2 1KGP Cookbook (v3) [Online]. The 
Enhancing Neuroimaging Genetics trhough Meta-Analysis (ENIGMA) Consortium. 
[Internet]. 2013. Available from: http://enigma.ini.usc.edu/wp-
content/uploads/2012/07/ENIGMA2_1KGP_cookbook_v3.pdf 
27.  Brett M. Region of interest analysis using an SPM toolbox [abstract]. Present 8th Int 
Conferance Funct Mapp Hum Brain. 2002 Jun 2;16(2):abstract 497.  
28.  Fritz H-C, Wittfeld K, Schmidt CO, Domin M, Grabe HJ, Hegenscheid K, et al. Current 
Smoking and Reduced Gray Matter Volume—a Voxel-Based Morphometry Study. 
Neuropsychopharmacology. 2014 Oct;39(11):2594–600.  
29.  Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition 
and the brain. Neuropsychol Rev. 2007 Sep;17(3):259–73.  
30.  Hong LE, Yang X, Wonodi I, Hodgkinson CA, Goldman D, Stine OC, et al. A CHRNA5 
Allele Related to Nicotine Addiction and Schizophrenia. Genes Brain Behav. 2011 
Jul;10(5):530–5.  
31.  Sutherland MT, Ray KL, Riedel MC, Yanes JA, Stein EA, Laird AR. Neurobiological 
Impact of Nicotinic Acetylcholine Receptor Agonists: An Activation Likelihood Estimation 
Meta-Analysis of Pharmacologic Neuroimaging Studies. Biol Psychiatry. 2015 Nov 
15;78(10):711–20.  
32.  Konova AB, Moeller SJ, Goldstein RZ. Common and distinct neural targets of treatment: 
changing brain function in substance addiction. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 
2):2806–17.  
33.  Hudkins M, O’Neill J, Tobias MC, Bartzokis G, London ED. Cigarette smoking and white 
matter microstructure. Psychopharmacology (Berl). 2012 Jan 4;221(2):285–95.  
34.  Paul RH, Grieve SM, Niaura R, David SP, Laidlaw DH, Cohen R, et al. Chronic cigarette 
smoking and the microstructural integrity of white matter in healthy adults: a diffusion 
tensor imaging study. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2008 Jan;10(1):137–
47.  
35.  Park H-J, Kim JJ, Lee S-K, Seok JH, Chun J, Kim DI, et al. Corpus callosal connection 
mapping using cortical gray matter parcellation and DT-MRI. Hum Brain Mapp. 2008 
May;29(5):503–16.  
41.   Eklund, Anders, Thomas E. Nichols, and Hans Knutsson. “Cluster Failure: Why fMRI     
        Inferences for Spatial Extent Have Inflated False-Positive Rates.” Proceedings of the   
        National Academy of Sciences 113, no. 28 (July 12, 2016): 7900–7905.  
 
 
 
 
 
26 
 
Figure Legends 
 
Figure 1. The different participant groups available from the IMAGEN study and used for the 
neuroimaging regression analyses (A, B) as well as for the genetic analyses (C). Non-smokers are 
represented with green bars (smoking score = 0). Smokers included in regression and genetic 
analyses had very low, low and moderate smoking exposure levels (smoking scores 1 to 6). 
Numbers on bars represent the total number of participants for each smoking score.  
 
Figure 2. A) Whole brain rendering of the T maps resulting from the brain voxel-wise regression 
analysis between GMV and smoking score. A significant negative correlation (initial threshold 
p<0.005; p<0.05 when corrected for multiple comparisons) was observed in the ventromedial 
prefrontal cortex (vmPFC). No positive correlations between GMV and smoking score were 
detected. B) The relationship between the vmPFC volume and future smoking at age 16 in 627 
adolescents who were smoking naïve at age 14. No significant correlation was observed with 
r=0.02 and p=0.9. C) The rs16969968 genotype effects on structural GMV in the vmPFC. A 2x3 
ANCOVA indicated that smoking status and the smoking-genotype interaction had significant 
effects on the vmPFC volume (p<0.0005 and p=0.026, respectively), where it was significantly 
decreased in smokers with the effect being largest in the carriers of the smoking-related high-risk 
genotype (AA). (*): significant difference with p<0.05. 
 
Figure 3. Alcohol use and performance IQ association with vmPFC volume in non-smokers. No 
significant correlations were observed in any of the analyses with R2≤0.0043 and p>0.1, suggesting 
that alcohol use and performance IQ are not correlated with vmPFC volume. vmPFC: ventromedial 
prefrontal cortex. 
 
Figure 4. Smoking status effects on white matter integrity. A) Whole brain rendering of the T map 
and Pearson’s correlation showing significant negative correlation between FA values in the corpus 
callosum ROI and smoking occasions, with r =-0.24 and p=5E-06. B) The regression between the 
ventromedial prefrontal cortex (vmPFC) volume and future smoking at age 16 in 531 adolescents 
who were smoking naïve at age 14 revealed no significant correlation relationship with r=0.02 and 
p=0.8. C) Pearson’s correlation test highlighting the significant positive correlation between FA 
values in the corpus callosum cluster and the vmPFC volume, with r =0.25 and p=0.00008. (*): 
significant difference with p<0.05. 
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Supplementary Table 1. Demographic information for the participants in regression and genetic 
analyses. Quantitative measures are expressed as mean ± standard deviation. NS: non-significant 
difference; (*): t test p < 0.05; (**): t test p < 0.005. (GMV): Grey Matter Volume; (FA): Fractional 
Anisotropy; (PDS): Pubertal Development State. 
 
 
 
 
 
 
 
Supplementary Table S2. Statistics and frequency of rs16969968 and rs1051730. Measures of 
Hardy-Weinberg Equilibrium (HW), Minor Allele Frequency (MAF), imputation quality and LD 
of the two SNPs are reported as observed in the full genotype sample of IMAGEN (1834 subjects). 
AA, GA and GG are the high-risk, intermediate risk and low-risk genotypes associated with 
Analysis  Smoking 
score 
Parental 
smoking 
score 
Age Sex 
(Females) 
Performance 
IQ 
Verbal 
IQ 
PDS Handedness 
(right 
handed) 
SES Alcohol 
use 
Regression 
between 
GMV and 
smoking 
scores 
Non-Smokers 0 1.4±0.9 14.5±0.4 48 % 111±14 114±13 3.6±0.7 91.1% 18.5±3.6 2.32±1.4 
Smokers 2.5±1.8 1.6±0.4 14.5±0.2 50 % 106±13 110±12 3.7±0.6 87.5% 17.7±4 3.8±1.7 
Non-smokers 
vs smokers    
  NS NS 
NS 
p
(χ2)
=0.72 ** NS NS 
NS 
p
(χ2)
=0.47 * ** 
Regression 
between 
FA and 
smoking 
scores 
Non-Smokers 0 1.3±0.7 14.5±0.3 48 % 111±14 114±13 3.6±0.7 90% 18.3±3.5 2.32±1.4 
Smokers 2.6±1.8 1.6±0.5 14.5±0.2 50 % 105±13 111±12 3.7±0.6 87.5% 17.9±4 3.8±1.7 
Non-smokers 
vs smokers    
  NS NS 
NS 
p
(χ2)
=0.72 ** NS NS 
NS 
p
(χ2)
=0.47 NS ** 
Genetic 
Non-Smokers 0 1.3±0.8 14.5±0.4 50% 110±14 112±15 3.6±0.7 89% 18.2±3.3 2.2±1.5 
Smokers 2.4±1.7 1.5±0.3 14.5±0.3 52% 106±13 109±15 3.6±0.6 87% 17.8±4 3.8±1.8 
Non-smokers 
vs smokers     
NS NS 
NS 
p
(χ2)
=0.7 ** NS NS 
NS 
p
(χ2)
=0.5 NS ** 
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smoking, respectively. The two SNPs are in tight LD and highly correlated (D’=1; R2=0.99). They 
are significantly associated with smoking (p=0.003) and have similar allele frequencies within non-
smokers and smokers.  
D′ : the d′ of the linkage equilibrium between the two loci. R2 , variance explained between the 
two loci. β: effect size of the association with smoking. 
 
 
 
This study shows morphological and functional brain changes associated with low smoking 
exposure in young adolescent smokers, which may underlie, at least in part, a genetic component 
associated with smoking. Our findings give insight into a mechanism involving genes, brain 
structure and brain function underlying why some teens find nicotine especially reinforcing and 
transition to repeated use leading to increased risk of lifetime dependence.  
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